Compare Globus Medical Inc. Class A Common Stock (GMED) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Matson Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Matson Inc trades at $235.22 (market cap $7.04B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Matson Inc pays a 0.65% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Matson Inc for 25 Days on average.
| GMED | MATX | |
|---|---|---|
Market Cap | $10.25B | $7.04B |
Volume | 1,059,528 | 295,660 |
Sector | Health | Industrials |
52-Week High | $96.82 | $238.60 |
52-Week Low | $58.33 | $93.22 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $9.76B | $7.64B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Matson (MATX) trades at $235.22, up 3.31% with strong bullish momentum supported by consistent earnings beats and positive technical indicators. The stock shows robust fundamentals with a 13.41% net income margin and 17.21% ROE, while valuation metrics remain reasonable with a P/E of 15.87. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 expected, driving positive sentiment.
Outlook remains positive with Wall Street analysts projecting 27.3% upside potential and strong institutional buying activity. Key risks include freight market volatility and competitive pressures, but the company's raised full-year guidance and dividend payments provide stability for investors seeking transportation sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
